⚡ DUAL AGONIST CLINICAL AUDIT: October 8, 2026 • Dual GIP + GLP-1 Up to 22.5% Weight Reduction • Flat $129/mo Access Open
⚡ ⚡ 2026 Dual Incretin Clinical Audit

Why Dual GIP + GLP-1 Agonists Outperform Single Peptides in Clinical Trials

Take this free 60-second clinical diagnostic to evaluate the dual incretin mechanism (GIP + GLP-1), discover why SURMOUNT-1 clinical trials achieved up to 22.5% body weight reduction, and see if you qualify for physician-monitored flat-rate Tirzepatide ($129/mo).

⚠️ ACCESS ALERT: DUAL AGONISM BREAKTHROUGH: While first-gen Semaglutide activates only GLP-1 receptors, Tirzepatide acts simultaneously on both GIP and GLP-1 receptors—supercharging adipocyte fat burning while reducing GI side effects.
✓
Instant 60-Second Dual Agonist Evaluation: Discover if next-gen incretin therapy matches your metabolic profile.
✓
Clinical Trial Superiority: Clinical trials demonstrated an average 52 lb weight loss (up to 22.5% total reduction).
✓
Locked Flat-Rate 503A Care: Access physician-supervised compounded Tirzepatide for just $129/mo all doses included up to 15mg.
🟢 35,620 Dual Agonist Audits Completed This Month • $0 Intake Fee
⚡ Question 1 of 10
10% Complete

What total weight reduction percentage are you aiming to achieve?

Calibrates required clinical potency tier: